Why Your Body Stops Responding to Leptin and Ghrelin When You're Obese

This is a narrative review article published in Nature Reviews Endocrinology. The authors synthesized findings from animal studies, cell biology experiments, and clinical observations to provide a comprehensive overview of leptin and ghrelin resistance mechanisms in obesity.

Understanding hormone resistance is central to solving the obesity epidemic. Many people assume weight gain is simply about willpower, but this review shows that obesity fundamentally alters the brain's hormonal communication system. By mapping the specific molecular breakdowns, researchers can identify precise targets for new anti-obesity drugs — potentially ones that restore hormone sensitivity rather than just mimicking or replacing these signals.

This review connects directly to the GLP-1 drug revolution. While semaglutide and tirzepatide bypass leptin and ghrelin pathways entirely by targeting incretin receptors, understanding why the body's own appetite hormones fail in obesity helps explain why these newer drugs are so effective — and why restoring endogenous hormone sensitivity remains a parallel research frontier. It also raises questions about whether GLP-1 drugs might indirectly improve leptin or ghrelin sensitivity.

As a review article, this paper synthesizes existing research rather than presenting new experimental data. Much of the mechanistic evidence comes from animal models (particularly rodents), which may not fully reflect human physiology. The review was published in 2017, so more recent discoveries about hormone resistance pathways may not be included.